Sign in to fuzzto save your conversations, follow your research and come back anytime.
Advanced Enzyme Tech
ADVENZYMES
NSE
BSE
NSEBSESectorHealthcare
296.00
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Profit margins and earnings face headwinds in Q1 FY27, while revenue and institutional ownership remain stable.
Finance costs eased from ₹8 Cr in Q1 FY26 to ₹6 Cr in Q1 FY27, lowering the interest burden.
EBITDA margin contracted from 33% in Q2 FY26 to 27% in Q1 FY27, reflecting pricing and cost pressures.
Europe revenue recovered from ₹95 Cr in Q4 FY26 to ₹132 Cr in Q1 FY27, highlighting regional demand strength.
Net profit declined from ₹453 Cr in Q4 FY26 to ₹386 Cr in Q1 FY27, signaling earnings headwinds.
Asia revenue grew from ₹177 Cr in Q1 FY26 to ₹242 Cr in Q1 FY27, sustaining overseas expansion.
Operating expenses stayed elevated at ₹1,487 Cr in Q1 FY27 compared to ₹1,328 Cr in Q3 FY26, squeezing profitability.
Polunin Capital increased its stake from 1.44% in Q2 FY26 to 2.58% in Q1 FY27, showing renewed accumulation.
India revenue softened from ₹1,061 Cr in Q4 FY26 to ₹937 Cr in Q1 FY27, indicating domestic demand weakness.
Orbimed Asia III maintained a constant 12.07% stake from Q1 FY26 to Q1 FY27, anchoring the institutional base.
ICICI Prudential MF reduced its stake from 3.08% in Q1 FY26 to 0.72% in Q1 FY27, showing fund exit.